A Phase I Ascending Dose Safety Study Of Intramuscular CTX0E03 In Patients With Lower Limb Ischaemia
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2018
Price : $35 *
At a glance
- Drugs ReN 009 (Primary)
- Indications Peripheral ischaemia
- Focus Adverse reactions
- Sponsors ReNeuron
- 31 Aug 2018 Biomarkers information updated
- 30 Jan 2018 Status changed from active, no longer recruiting to completed.
- 23 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018.